Literature DB >> 30882184

Bivalirudin use in acute coronary syndrome patients undergoing percutaneous coronary interventions in Poland: Clinical update from expert group of the Association on Cardiovascular Interventions of the Polish Cardiac Society.

Łukasz Kołtowski1, Jacek Legutko2, Krzysztof J Filipiak3, Artur Dziewierz4, Stanisław Bartuś5, Paweł Buszman5,6, Piotr Buszman7,8, Dariusz Ciećwierz9, Maciej Dąbrowski10, Sławomir Dobrzycki11, Robert Gil12, Jarosław Gorący13, Marek Grygier14, Miłosz Jaguszewski9, Janusz Kochman3, Jacek Kubica15, Wiktor Kuliczkowki16, Piotr Lodziński3, Andrzej Ochała17, Krzysztof Reczuch18, Adam Witkowski10, Wojciech Wojakowski19, Jarosław Wójcik20, Dariusz Dudek21,22.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30882184      PMCID: PMC8086680          DOI: 10.5603/CJ.2019.0029

Source DB:  PubMed          Journal:  Cardiol J        ISSN: 1898-018X            Impact factor:   2.737


× No keyword cloud information.
  24 in total

1.  Bivalirudin started during emergency transport for primary PCI.

Authors:  Philippe Gabriel Steg; Arnoud van 't Hof; Christian W Hamm; Peter Clemmensen; Frédéric Lapostolle; Pierre Coste; Jurrien Ten Berg; Pierre Van Grunsven; Gerrit Jan Eggink; Lutz Nibbe; Uwe Zeymer; Marco Campo dell' Orto; Holger Nef; Jacob Steinmetz; Louis Soulat; Kurt Huber; Efthymios N Deliargyris; Debra Bernstein; Diana Schuette; Jayne Prats; Tim Clayton; Stuart Pocock; Martial Hamon; Patrick Goldstein
Journal:  N Engl J Med       Date:  2013-10-30       Impact factor: 91.245

2.  [Bivalirudine use in the acute myocardial infarction in patients undergoing percutaneous coronary interventions: consensus statement of experts from the Cardiovascular Pharmacotherapy Working Group and the Association on Cardiovascular Interventions of the Polish Cardiac Society].

Authors:  Beata Wożakowska-Kapłon; Maciej Lesiak; Andrzej Ochała; Adam Witkowski; Krzysztof J Filipiak
Journal:  Kardiol Pol       Date:  2014       Impact factor: 3.108

3.  Comparative cost-effectiveness of anticoagulation with bivalirudin or heparin with and without a glycoprotein IIb/IIIa-receptor inhibitor in patients undergoing percutaneous coronary intervention in Sweden: a decision-analytic model.

Authors:  Sixten Borg; Ulf Persson; Kristina Allikmets; Karin Ericsson
Journal:  Clin Ther       Date:  2006-11       Impact factor: 3.393

4.  Bivalirudin for patients with acute coronary syndromes.

Authors:  Gregg W Stone; Brent T McLaurin; David A Cox; Michel E Bertrand; A Michael Lincoff; Jeffrey W Moses; Harvey D White; Stuart J Pocock; James H Ware; Frederick Feit; Antonio Colombo; Philip E Aylward; Angel R Cequier; Harald Darius; Walter Desmet; Ramin Ebrahimi; Martial Hamon; Lars H Rasmussen; Hans-Jürgen Rupprecht; James Hoekstra; Roxana Mehran; E Magnus Ohman
Journal:  N Engl J Med       Date:  2006-11-23       Impact factor: 91.245

5.  Prasugrel versus clopidogrel in patients with acute coronary syndromes.

Authors:  Stephen D Wiviott; Eugene Braunwald; Carolyn H McCabe; Gilles Montalescot; Witold Ruzyllo; Shmuel Gottlieb; Franz-Joseph Neumann; Diego Ardissino; Stefano De Servi; Sabina A Murphy; Jeffrey Riesmeyer; Govinda Weerakkody; C Michael Gibson; Elliott M Antman
Journal:  N Engl J Med       Date:  2007-11-04       Impact factor: 91.245

6.  Stent Thrombosis in Drug-Eluting or Bare-Metal Stents in Patients Receiving Dual Antiplatelet Therapy.

Authors:  Dean J Kereiakes; Robert W Yeh; Joseph M Massaro; Priscilla Driscoll-Shempp; Donald E Cutlip; P Gabriel Steg; Anthony H Gershlick; Harald Darius; Ian T Meredith; John Ormiston; Jean-François Tanguay; Stephan Windecker; Kirk N Garratt; David E Kandzari; David P Lee; Daniel I Simon; Adrian Corneliu Iancu; Jaroslaw Trebacz; Laura Mauri
Journal:  JACC Cardiovasc Interv       Date:  2015-10       Impact factor: 11.195

7.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes.

Authors:  Lars Wallentin; Richard C Becker; Andrzej Budaj; Christopher P Cannon; Håkan Emanuelsson; Claes Held; Jay Horrow; Steen Husted; Stefan James; Hugo Katus; Kenneth W Mahaffey; Benjamin M Scirica; Allan Skene; Philippe Gabriel Steg; Robert F Storey; Robert A Harrington; Anneli Freij; Mona Thorsén
Journal:  N Engl J Med       Date:  2009-08-30       Impact factor: 91.245

Review 8.  Epidemiology of coronary heart disease and acute coronary syndrome.

Authors:  Fabian Sanchis-Gomar; Carme Perez-Quilis; Roman Leischik; Alejandro Lucia
Journal:  Ann Transl Med       Date:  2016-07

9.  Bivalirudin versus heparin in percutaneous coronary intervention-a systematic review and meta-analysis of randomized trials stratified by adjunctive glycoprotein IIb/IIIa strategy.

Authors:  Mahesh Anantha-Narayanan; Dixitha Anugula; Nagarjuna R Gujjula; Yogesh N V Reddy; Janani Baskaran; Manu Kaushik; Venkata M Alla; Ganesh Raveendran
Journal:  J Thorac Dis       Date:  2018-06       Impact factor: 2.895

10.  Anticoagulants: A Review of the Pharmacology, Dosing, and Complications.

Authors:  Mohammed Alquwaizani; Leo Buckley; Christopher Adams; John Fanikos
Journal:  Curr Emerg Hosp Med Rep       Date:  2013-04-21
View more
  1 in total

1.  Occurrence and Risk Factors of Adverse Drug Reactions in Patients Receiving Bivalirudin as Anticoagulant During Percutaneous Coronary Intervention: A Prospective, Multi-Center, Intensive Monitoring Study.

Authors:  Ping Li; Hongyan Zhang; Caidong Luo; Zheng Ji; Zeqi Zheng; Zhenyong Li; Fan Wu; Jinlong Li; Lang Hong
Journal:  Front Cardiovasc Med       Date:  2022-04-29
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.